Structure Therapeutics Inc.
- Open
- 46.02
- Day high
- 46.85
- Day low
- 45.60
- Prev close
- 45.91
- Volume
- 22K
- Mkt cap
- $3.3B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 2.4
- P/S
- —
- Yield
- —
- Per share
- —
- ▼Insiders net selling $0 over the last 3 months (0 open-market buys, 10 sales)
- 🏛Institutions reducing (13F)
Structure Therapeutics Inc. (GPCR) is a Healthcare company listed on NASDAQ. The stock is up 129% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 10 sales (SEC Form 4).
Structure Therapeutics Inc. (GPCR) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 3 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
GPCR earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 6, 2026 | $-0.39 | $-0.49 | -25.6% | — | — |
| May 7, 2026 | $-0.39 | $-0.35 | +10.3% | — | — |
| Nov 6, 2025 | $-0.36 | $-0.37 | -2.8% | — | — |
| May 8, 2025 | $-0.24 | $-0.27 | -12.5% | — | — |
| Feb 27, 2025 | $-0.23 | $-0.22 | +4.3% | $2M | — |
| Aug 8, 2024 | $-0.23 | $-0.18 | +21.7% | — | — |
| May 9, 2024 | $-0.21 | $-0.19 | +9.5% | — | — |
| Mar 8, 2024 | $-0.21 | $-0.17 | +19.0% | $1M | — |
| Nov 14, 2023 | $-0.29 | $-0.62 | -113.8% | — | — |
| Aug 10, 2023 | $-0.28 | $-0.60 | -114.3% | — | — |
| May 11, 2023 | $-0.41 | $-0.25 | +39.0% | — | — |
| Sep 30, 2022 | — | $-0.12 | — | — | — |
GPCR insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 19, 2026 | Lin Xichenofficer: CHIEF SCIENTIFIC OFFICER | Sell | 400 | — |
| Aug 19, 2026 | Lin Xichenofficer: CHIEF SCIENTIFIC OFFICER | Option | 11,817 | $0.34 |
| Aug 19, 2026 | Lin Xichenofficer: CHIEF SCIENTIFIC OFFICER | Sell | 3,020 | — |
| Aug 19, 2026 | Lin Xichenofficer: CHIEF SCIENTIFIC OFFICER | Sell | 519 | — |
| Aug 7, 2026 | Berrios John Josephofficer: Chief Commercial Officer | Grant | 140,766 | — |
| Aug 7, 2026 | Berrios John Josephofficer: Chief Commercial Officer | Grant | 174,612 | $17.54 |
| Aug 5, 2026 | Lin Xichenofficer: CHIEF SCIENTIFIC OFFICER | Sell | 839 | — |
| Aug 5, 2026 | Lin Xichenofficer: CHIEF SCIENTIFIC OFFICER | Option | 11,817 | $0.34 |
| Aug 5, 2026 | Lin Xichenofficer: CHIEF SCIENTIFIC OFFICER | Sell | 3,100 | — |
| Jul 24, 2026 | FMR LLC10 percent owner, other: See Remark 1 | Sell | 16,085 | — |
| Jul 24, 2026 | FMR LLC10 percent owner, other: See Remark 1 | Sell | 1,367 | — |
| Jul 15, 2026 | Lin Xichenofficer: CHIEF SCIENTIFIC OFFICER | Sell | 6,278 | — |
| Jul 15, 2026 | Lin Xichenofficer: CHIEF SCIENTIFIC OFFICER | Sell | 1,600 | — |
| Jul 15, 2026 | Lin Xichenofficer: CHIEF SCIENTIFIC OFFICER | Option | 23,634 | $0.34 |
| Jun 29, 2026 | Lin Xichenofficer: CHIEF SCIENTIFIC OFFICER | Sell | 7,878 | — |
Source: GPCR SEC Form 4 filings, latest Aug 19, 2026. For informational purposes only — not investment advice.
See the full GPCR insider & 13F page →Structure Therapeutics Inc. company profile
Overview
Structure Therapeutics Inc. (NASDAQ:GPCR) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in South San Francisco, California. The company was formerly known as ShouTi Inc. before rebranding and went public in February 2023. Structure Therapeutics focuses on developing novel oral small molecule therapeutics targeting G-protein-coupled receptors (GPCRs) to treat chronic diseases with significant unmet medical needs, particularly in diabetes, obesity, and pulmonary diseases.
Business
Structure Therapeutics operates in the biotechnology sector, specifically focusing on drug discovery and development targeting G-protein-coupled receptors (GPCRs). GPCRs are a large family of cell surface proteins that detect molecules outside the cell and activate cellular responses, making them crucial targets for pharmaceutical intervention. These receptors are involved in virtually every physiological process and represent the target for approximately 35% of all marketed drugs. The company's approach centers on developing oral small molecule therapeutics rather than injectable biologics, which offers potential advantages in patient convenience, compliance, and manufacturing costs. Structure Therapeutics has three main drug candidates in development: 1. GSBR-1290 represents the company's lead program - an oral, biased small molecule agonist of the glucagon-like-peptide-1 (GLP-1) receptor. This targets the same pathway as popular injectable diabetes and obesity drugs like Ozempic and Wegovy, but in pill form. The GLP-1 receptor regulates blood sugar levels and appetite, making it a validated target for type 2 diabetes and obesity treatment. 2. ANPA-0073 is a biased agonist targeting the apelin receptor, a GPCR implicated in serious lung conditions including idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. IPF is a progressive scarring disease of the lungs with limited treatment options and poor prognosis. 3. LTSE-2578 is an oral small molecule antagonist of the lysophosphatidic acid 1 (LPA1) receptor, also being developed for IPF treatment. This represents an alternative mechanism to address the same serious lung condition. As a clinical-stage company, Structure Therapeutics currently generates no revenue from product sales, with all three candidates still in various phases of clinical development and regulatory approval processes.
Revenue model
Structure Therapeutics currently operates on a research and development business model typical of early-stage biotechnology companies. The company does not yet generate revenue from product sales, as all its drug candidates remain in clinical development phases. Instead, the company funds its operations through equity financing from investors who are betting on the future commercial potential of its drug pipeline. The company's future revenue model will likely center on product sales of approved therapeutics, potentially supplemented by licensing agreements or partnerships with larger pharmaceutical companies. Given that Structure Therapeutics is developing treatments for large market opportunities - the global GLP-1 receptor agonist market for diabetes and obesity is projected to reach tens of billions of dollars - successful drug approval could generate substantial revenues. Several factors could significantly impact the company's future profitability margins. Positive factors include the large addressable markets for diabetes, obesity, and pulmonary diseases, the potential cost advantages of oral formulations over injectable competitors, and the company's focus on validated drug targets with proven clinical efficacy. The oral delivery mechanism could provide competitive advantages in patient compliance and manufacturing scalability. Negative factors include intense competition in the GLP-1 space from established players like Novo Nordisk and Eli Lilly, the high costs and risks associated with clinical trials and regulatory approval processes, and the technical challenges of developing effective oral formulations for targets traditionally addressed by injectable drugs. Additionally, the company faces the typical biotech risks of clinical trial failures, regulatory setbacks, and the substantial capital requirements needed to bring drugs through the lengthy development and approval process.
Competitive moat
Structure Therapeutics currently possesses a limited but potentially significant moat based on its proprietary technology platform and scientific expertise in GPCR drug development. The company's primary competitive advantage lies in its ability to develop oral small molecule drugs targeting receptors that have traditionally required injectable formulations. This technical capability, if successfully demonstrated in clinical trials, could provide meaningful differentiation in markets dominated by injectable therapies. The company's intellectual property portfolio around its specific drug candidates and formulation approaches represents another potential moat component. However, the strength of this protection depends on the breadth and enforceability of patents, which is difficult to assess without detailed patent analysis. The moat faces significant challenges from well-established pharmaceutical giants with vastly superior resources. In the GLP-1 space, companies like Novo Nordisk and Eli Lilly have deep pockets, extensive clinical trial capabilities, established regulatory relationships, and strong market positions with already-approved products. These companies are also working on their own oral formulations, potentially eroding Structure Therapeutics' differentiation. The company's moat is further limited by the early stage of its development programs. Clinical-stage biotechnology companies inherently lack the protective moats that come with approved products, established customer relationships, and proven revenue streams. The competitive landscape could shift dramatically during the multi-year development timeline, and larger competitors could potentially develop superior oral formulations or alternative approaches that render Structure Therapeutics' programs less compelling. The strength of any future moat will ultimately depend on clinical trial results, regulatory approval success, and the company's ability to establish market presence before larger competitors launch competing oral therapies.
Risks & safety
Structure Therapeutics exhibits a strong financial safety profile typical of a well-funded, early-stage biotech company, though with the inherent risks of pre-revenue operations. • Cash position and burn rate: The company maintains $152.1 million in cash and short-term investments as of Q1 2025, with quarterly operating cash burn of approximately $52 million, providing roughly 3 quarters of runway at current spending levels. • Debt and solvency: Minimal debt burden with debt-to-equity ratio of just 0.9%, indicating very low financial leverage and solvency risk. Current ratio of 23.3x demonstrates excellent short-term liquidity. • Valuation considerations: Trading at negative P/E ratios due to losses, but Graham net-net working capital ratio of 4.6x suggests the stock trades below liquidation value on a per-share basis. • Balance sheet strength: Total assets of $866.5 million against minimal liabilities of $41.9 million provides substantial financial cushion. • Operating losses: Increasing quarterly losses from $26 million in Q2 2024 to $47 million in Q1 2025 reflect ramping clinical trial expenses, requiring careful cash management and likely future financing needs.
Recent development
Based on the financial data available, Structure Therapeutics has been in a significant expansion phase since its 2023 IPO, with operating expenses and cash burn increasing substantially as the company advances its clinical programs. The quarterly operating cash burn has nearly doubled from $26 million in Q2 2024 to $52 million in Q1 2025, indicating accelerated clinical trial activities and expanded operations. The company appears to have successfully raised substantial capital following its public listing, with cash and short-term investments peaking at $382 million in Q2 2024 before declining to current levels of $152 million. This capital infusion has enabled the company to aggressively pursue its clinical development programs across all three drug candidates. The increasing expense trajectory suggests Structure Therapeutics is likely conducting multiple clinical trials simultaneously across its GPCR-targeted pipeline. The substantial ramp-up in spending from 2023 to 2024, with annual operating cash flow losses increasing from $79 million to $117 million, reflects the typical pattern of a biotech company moving from early-stage research into more expensive Phase II and potentially Phase III clinical trials. The company's financial positioning indicates it has been prioritizing speed of development over capital conservation, likely reflecting management confidence in their programs and the competitive pressures in the GLP-1 and pulmonary disease markets. However, the accelerating burn rate suggests the company will need to secure additional funding or achieve significant clinical milestones within the next 12-18 months to maintain its current development pace.
GPCR company profile · for informational purposes only — not investment advice.
Track GPCR with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free